Planet Innovation provides contract design and manufacturing expertise to companies producing instruments and consumables for the cell and gene therapy industry. We specialize in developing closed processing solutions that support the autologous manufacturing workflow.
We have an expert in-house laboratory team as well as built-for-purpose facilities, including multiple cleanrooms and manufacturing equipment, that enable us to provide you with the necessary skills all under one roof.
Get in touchPI has a large team of designers, engineers, manufacturing specialists and cell therapy experts all under one roof. We understand that the cell and gene therapy manufacturing process is complex – so when developing any individual unit solution, it is critical to understand the upstream and downstream interfaces. PI’s end-to-end services also include digital capabilities to complement our instrument and consumable expertise.
PI operates world-class facilities that include fully equipped medical development laboratories, specialist wet lab facilities for live cell handling, 120,000 sq.ft. of ISO 13485:2016 certified manufacturing floor space and ISO Class 7 cleanrooms. We have rigorous quality systems and a disciplined approach to delivering the highest standard of products to our clients.
From counterflow centrifugation systems used for cell wash and concentration steps, to single use disposable kits, PI has deep experience in helping companies produce solutions that reduce the time and cost of manufacturing cell and gene therapy products. For over 10 years we have partnered with world-leading companies to help them develop their custom solutions and advance the cell and gene therapy industry.
Brian Hanrahan, VP Cell and Gene Therapy, explains why your instrument needs to integrate into your users’ workflow.
Brian Hanrahan, VP of C> explains why single-use disposables are a crucial element in any cell and gene manufacturing tool. Learn more about what you need to consider when developing disposables for cell therapy manufacturing
Brian Hanrahan, VP Cell & Gene Therapy shares some insights on what investors look for when assessing funding opportunities.
